- Home
- Test Categories
- Allergy Testing
- Autoimmune Diseases
- Blood and Blood Diseases
- Cancer Detection
- Diabetes
- DNA, Paternity and Genetic Testing
- Drug Screening
- Environmental Toxin Testing
- Female Specific Tests
- Fitness, Nutrition and Anti-Aging
- Gastrointestinal Diseases
- General Wellness
- Heart Health and Cholesterol
- Hormones and Metabolism
- Immunization Check
- Infectious Diseases
- Infertility Testing
- Kidney Diseases
- Liver Diseases
- Male Specific Tests
- Musculoskeletal Diseases
- Sexually Transmitted Diseases (STD's)
- Therapeutic Drug Monitoring
- Thyroid Diseases
- - STD Testing
- About STD Testing
- Chlamydia and Gonorrhea Test
- Cytomegalovirus (CMV) Antibodies, IgG
- Cytomegalovirus (CMV) Antibodies, IgM, Quantitative
- Epididymitis Screen
- Hepatitis A and B Immune Status Profile Test
- Hepatitis A and B Profile, Acute Diagnostic
- Hepatitis A and B Profile, Comprehensive
- Hepatitis A Antibody, IgM
- Hepatitis A Antibody, Total
- Hepatitis A Profile, Acute verses Chronic Differentiation
- Hepatitis B and C Profile Test (Comprehensive)
- Hepatitis B Core Antibody, IgG, IgM, Differentiation
- Hepatitis B Core Antibody, IgM
- Hepatitis B Core Antibody, Total
- Hepatitis B Patient Management Profile Test
- Hepatitis B Profile
- Hepatitis B Surface Antibody Test
- Hepatitis C Antibody Test
- Hepatitis C Virus (HCV) Antibody, With Reflex to RIBA
- Hepatitis C Virus (HCV), RNA PCR, Qualitative
- Hepatitis Panel, Acute
- Hepatitis Profile II (Diagnostic Follow-up)
- Herpes Simplex Virus (HSV) Type I and II IgG
- Herpes Simplex Virus (HSV) Type II IgG
- Herpes Simplex Virus (HSV), Type I and II IgM
- HIV-1 and HIV-2 Screen
- HIV-1 Antibodies Test
- HIV-1 DNA RT- PCR With HIV Antibodies , ICMA
- HIV-2 Antibodies
- HIV-2 Proviral DNA by PCR
- Human Immunodeficiency Virus 1 (HIV-1) RNA (bDNA)
- Mycoplasma/Ureaplasma, Real-Time PCR
- Soluble Liver Antigen (SLA) IgG Antibody (Autoimmune Hepatitis)
- STD Recent Exposure Panel
- STD Urinary Tract Infection Panel
- Syphilis (RPR) Test
- Treponema pallidum Antibodies (TP-PA)
- Ultimate STD Panel
- Ultimate Viral STD Panel
- See All STD Tests
- - Blood Tests
- Allergy Testing
- Autoimmune Disease Testing
- Blood Disorder and Blood Disease Testing
- Cancer Detection Testing
- Diabetes Testing
- DNA, Paternity and Genetic Testing
- Drug Screening Testing
- Environmental Testing
- Female-Specific Testing
- Fitness, Nutrition and Anti-Aging Testing
- Gastrointestinal Disease Testing
- General Wellness Testing
- Heart Health and Cholesterol Testing
- Hormone Blood Tests
- Immunization Testing
- Infectious Disease Testing
- Infertility Testing
- Kidney Disease Testing
- Liver Function Tests
- Musculoskeletal Disorders Testing
- Prostate Testing
- Therapeutic Drug Monitoring Testing
- Thyroid Testing
- - All Tests
- Lab Locations
- Why Online Lab Tests
- How it Works
- About Us
- FAQ
- Health Resources
Questions?
1.877.283.7882
1.877.283.7882
Private MD News
Home | News | Cancer Detection and Tumor MarkersDrug testing study shows reduced occurrence of brain tumors
Updated: 2009-10-13 22:11:16 CST Category: Cancer Detection and Tumor Markers
by Brendan Missett
Lab testing of the drug vorinostat demonstrated that the medication is able to cross the blood-brain barrier and reduce the occurrence of metastatic tumors in mice.
The new study, which appears in the September 29 online issue of Clinical Cancer Research, demonstrated that vorinostat reduced the development of large metastatic tumors in mice by 62 percent compared a group of mice that did not receive the drug.
For humans, vorinostat has been FDA approved for the treatment of cutaneous T-cell lymphoma, but has only been used experimentally as treatment of other cancers. The researchers, from the National Cancer Institute, say that this study may provide insight regarding the prevention of breast cancer's spread to the brain in diseased patients. Brain metastases of breast cancer have been untreatable because of the blood-brain barrier.
"Drugs that can cross the blood-brain barrier and reduce the size and incidence of metastatic tumors are urgently needed," said Dr Patricia S. Steeg, the study's author. Researchers believe the drug works by breaking strands of DNA and lowering the function of a repair gene, preventing cancer cells from restoring and metastasizing.
The National Institutes of Health determined that about 20 percent of breast cancer patients diagnosed with brain metastases survive past one year.
Related Articles from Private MD:
-
Study finds new cause of rare bone cancer
-
Studies of a rare cancer may prompt STD testing
-
Self-examination recommended to assess need of skin cancer tests
-
Research identifies risks in types of radiation therapy
-
National Cancer Institute attacks disease in Hispanic communities
Subscribe to Private MD Health News RSS Feed: 
Visit the Health News Archive: Click Here
Questions about online blood testing or how to order a lab test? Click here to get started or call us toll-free at 1.877.283.7882. Our certified professionals are ready to assist you.
